Rani Therapeutics Holdings (RANI) Debt to Equity (2020 - 2025)
Rani Therapeutics Holdings has reported Debt to Equity over the past 6 years, most recently at -$1.72 for Q3 2025.
- Quarterly results put Debt to Equity at -$1.72 for Q3 2025, down 135.14% from a year ago — trailing twelve months through Sep 2025 was -$1.72 (down 135.14% YoY), and the annual figure for FY2024 was $7.05, up 510.19%.
- Debt to Equity for Q3 2025 was -$1.72 at Rani Therapeutics Holdings, up from -$1.88 in the prior quarter.
- Over the last five years, Debt to Equity for RANI hit a ceiling of $7.05 in Q4 2024 and a floor of -$3.91 in Q1 2025.
- Median Debt to Equity over the past 5 years was $0.28 (2022), compared with a mean of $0.86.
- Biggest five-year swings in Debt to Equity: soared 199690.27% in 2023 and later crashed 293.11% in 2025.
- Rani Therapeutics Holdings' Debt to Equity stood at $0.0 in 2021, then skyrocketed by 37902.63% to $0.39 in 2022, then surged by 193.18% to $1.15 in 2023, then soared by 510.19% to $7.05 in 2024, then plummeted by 124.44% to -$1.72 in 2025.
- The last three reported values for Debt to Equity were -$1.72 (Q3 2025), -$1.88 (Q2 2025), and -$3.91 (Q1 2025) per Business Quant data.